Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33 + cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2 + cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicate IL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE.
Introduction
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) and one of the leading causes of neurological disability in young adults, affecting around 2.5 million people worldwide (Pugliatti et al., 2002) . While prevalence rates vary, particularly high levels are observed in North America (around 100 per 100,000 population) and the UK (200 per 100,000) (Mackenzie et al., 2014) . A recent study suggested annual costs to the UK of approximately £2.3 billion (Fineberg et al., 2013) . At present there is no cure with current treatments limited to management of symptoms and relapses, therefore further research is crucial to develop novel therapies.
While the precise aetiology is not yet fully understood, MS is thought to be initiated by autoreactive T lymphocytes infiltrating the CNS where they are activated by myelin and axonal antigens via antigen presenting cells (APCs) (Compston and Coles, 2008; Weiner, 2008) . This is followed by secretion of proinflammatory and cytotoxic mediators which leads to recruitment and activation of other immune cells including B cells, dendritic cells (DCs) and macrophages as well as activation of CNS resident cells (e.g. astrocytes and microglia). The ensuing inflammatory response results in demyelination, axonal loss, lesion development and subsequent neurological disability (Compston and Coles, 2008; Weiner, 2008) .
Alemtuzumab is a monoclonal antibody that binds to CD52, a glycosylated cell-surface protein that is highly expressed on T and B lymphocytes but is also found at lower levels on other immune cells such as natural killer (NK) cells, monocytes, macrophages and DCs (Rao et al., 2012) . It was originally used in the treatment of some types of cancer including chronic lymphocytic leukaemia and cutaneous T-cell lymphoma (Cox et al., 2005; Zhang et al., 2013) . Its therapeutic action is proposed to be via the depletion of T and B lymphocytes followed by a gradual repopulation but with an altered repertoire consisting of increased regulatory T cells (Tregs) relative to other CD4 + T cells and a shift in cytokine production towards a more anti-inflammatory profile (Cox et al., 2005; Pant et al., 2016; Thompson et al., 2010) . Due to the key roles for both T and B lymphocytes in MS pathogenesis, alemtuzumab underwent successful clinical trials and was subsequently approved for use in MS. It has been shown to reduce relapse rate and sustained accumulation of disability in patients with RRMS (Cohen et al., 2012; Coles et al., 2012) . However the exact mechanism of action
